Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 2, 1997, Pages 677-689

  Cook, Jacquelynn J ^a   Sitko, Gary R ^a   Holahan, Marie A ^a   Stranieri, Maria T ^a   Glass, Joan D ^a   Askew, Ben C ^a   Mcintyre, Charles J ^a   Claremon, David A ^a   Baldwin, John J ^a   Hartman, George D ^a   Gould, Robert J ^a   Lynch Jr , Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; N [(4 METHYLPHENYL)SULFONYL] 3 [[[5,6,7,8 TETRAHYDRO 4 OXO 5 [2 (4 PIPERIDINYL)ETHYL] 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 2 YL]CARBONYL]AMINO]ALANINE; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHESUS MONKEY; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ANIMALS; AZEPINES; BLEEDING TIME; DISEASE MODELS, ANIMAL; DOGS; DRUG ADMINISTRATION ROUTES; FIBRINOLYTIC AGENTS; MACACA MULATTA; PAN TROGLODYTES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SULFONAMIDES; THROMBOSIS;

EID: 8244255012     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. AIKEN, J. W., GORMAN, R. R. AND SHEBUSKI, R. J.: Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 17: 483-494, 1979.
2. ASKEW, B. C., BEDNAR, B., BEDNAR, R. A., CLAREMON, D. A., COOK, J. J., MCINTYRE, C. J., HUNT, C. A., GOULD., R. J., LYNCH, R. J., LYNCH, J. J., GAUL, S. L., STRANIERI, M. T., SITKO, G. R., HOLAHAN, M. A., GLASS, J. D., HAMILL, T., GORHAM, L. M., PRUEKSARITANONT, T., BALDWIN, J. J. AND HARTMAN, G. D.: Nonpeptide glycoprotien IIb/IIIa inhibitors. XX. Design and synthesis of orally active, long-acting nonpeptide fibrinogen antagonists. J. Med. Chem., in press.
3. BARRETT, J. S., MURPHY, G., PEERLINCK, K., DELEPELEIRE, I., GOULD, R. J., PANEBIANCO, R. J., HAND, E., DECKMYN, H., VERMYLEN, J. AND ARNOUT, J.: Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin. Pharmacol. Ther. 56: 377-388, 1994.
4. BEDNAR, B., CUNNINGHAM, M. E., MCQUENEY, P. A., EGBERTSON, M. S., ASKEW, B. C., BEDNAR, R. A., HARTMAN, G. D. AND GOULD, R. J.: Flow cytometric measurement of kinetic equilibrium binding parameters of RGD ligands in binding to GPIIb/IIIa on platelets. Cytometry. in press.
5. BEDNAR, R. A., GAUL, S. L., COOK, J. J., ASKEW, B. C., HARTMAN, G. D., GOULD, R. J. AND BEDNAR, B.: Novel mechanism for long acting GPIIb/IIIa antagonists. Circulation 94: I-98, 1996.
6. CARTEAUX, J.-P., STEINER, B. AND ROUX, S.: Ro 44-9883, a new non-peptidic GPIIb/IIIa antagonist prevents platelet loss in a guinea pig model of extracorporeal circulation. Thromb. Haemostas. 70: 817-821, 1993.
7. CHRISTOPOULUS, C., MACKIE, I., LAHIRI, A. AND MACHIN, S.: Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul. Fibrinolysis 4: 729-737, 1993.
8. COLLER, B. S., FOLTS, J. D., SMITH, S. R., SCUDDER, L. E. AND JORDAN, R.: Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 80: 1766-1774, 1989.
9. COLLER, B. S., ANDERSON, K. AND WEISMAN, H. F.: New antiplatelet agents: Platelet GPIIb/IIIa antagonists. Thromb. Haemost. 74: 302-308, 1995.
10. CONNOLLY, T. M., CONDRA, C., FENG, D.-M., COOK, J. J., STRANIERI, M. T., REILLY, C. F., NUTT, R. F. AND GOULD, R. J.: Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb. Haemost. 72: 627-633, 1994.
11. COOK, J. J., GLASS, J. D., SITKO, G. R., HOLAHAN, M. A., STUPIENSKI, R. F., WALLACE, A. A., STUMP, G. L., GEHRET, J. R., HAND, E. L., ASKEW, B. C., HARTMAN, G. D., GOULD, R. J. AND LYNCH, J. J.: Nonpeptide glycoprotein IIb/IIIa inhibitors. 14. Oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury. Circulation. in press.
12. COOK, J. J., HOLAHAN, M. A., LYLE, E. A., RAMJIT, D. R., SITKO, G. R., STRANIERI, M. T., STUPIENSKI, R. F., WALLACE, A. A., HAND, E. L., GEHRET, J. R., KOTHSTEIN, T., DRAG, M. D., MCCORMICK, G. Y., PERKINS, J. J., IHLE, N. C., DUGGAN, M. E., HARTMAN, G. D., GOULD, R. J. AND LYNCH, J. J.: Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J. Pharmacol. Exp. Ther. 278: 62-73, 1996.
13. EPIC INVESTIGATORS: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N. Engl. J. Med. 330: 956-961, 1994.
14. FOLTS, J. D.: A model of experimental arterial platelet thrombosis, platelet inhibitors, and their possible clinical relevance: An update. Cardiovasc. Rev. Rep. 11: 10-26, 1990.
15. FRISHMAN, W. H., BURNS, B., ATAC, B., ALTURK, N., ALTAJAR, B. AND LERRICK, K.: Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am. Heart J. 130: 877-892, 1995.
16. GENETTA, T. B. AND MAUARO, V. F.: Abciximab: A new antiaggregant used in angioplasty. Ann. Pharmacother. 30: 251-257, 1996.
17. HARRINGTON, R. A., SCHULMAN, S. P., KLEIMAN, N. S., LINCOFF, A. M., GOLDSCHMIDT-CLERMONT, P. J., JOSEPH, D., SIGMON, K. N., PARKER, J., MARCHANT, K. AND KITT, M. M.: Profound sustained and reversible platelet inhibition following administration of a glycoprotein IIb/IIIa inhibitor with and without heparin in patients with unstable angina. Circulation 90: I-232, 1994.
18. HARRINGTON, R. A., KLEIMAN, N. S., KOTTKE-MARCHANT, K., LINCOFF, M., TCHENG, J. E., SIGMON, K. N., JOSEPH, D., RIOS, G., TRAINOR, K., ROSE, D., GREENBERG, C. S., KITT, M. M., TOPOL, E. J. AND CALIFF, R. M.: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am. J. Cardiol. 76: 1222-1227, 1995.
19. JONES, C. R., AMBROS, R. J., RAPOLD, H. J., STEINER, B., WELLER, T., VAN HEININGEN, H. J. M. J., JONKMAN, J. H. G. AND HADVARY, P.: Ro 44-9883: A novel non peptide GPIIb/IIIa antagonist in man. Thromb. Haemost. 69: 560, 1993.
20. KEREIAKES, D., KLEIMAN, N., AMBROSE, J., COHEN, M., RODRIGUEZ, S., PALABRICA, T., HERRMANN, H. C., SUTTON, J., WEAER, S. W., MCKEE, D. AND SAX, F. L.: A dosing study in high-risk PTCA of MK-383, a platelet IIb/IIIa antagonist. Circulation 90: I-21, 1994.
21. KLEIMAN, N. S., OHMAN, E. M., CALIFF, R. M., GEORGE, B. S., KEREIAKES, D., AGUIRRE, F. V., WEISMAN, H., SCHAIBLE, T. AND TOPOL, E. J.: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J. Am. Coll. Cardiol. 22: 381-389, 1993.
22. LIND, S. E.: The bleeding time does not predict surgical bleeding. Blood 77: 2547-2552, 1991.
23. LYNCH, J. J., JR., COOK, J. J., SITKO, G. R., HOLAHAN, M. A., RAMJIT, D. R., MELLOTT, M. J., STRANIERI, M. T., STABILITO, I. I., ZHANG, G., LYNCH, R. J., MANNO, P. D., CHANG, C. T.-C., EGBERTSON, M. S., HALCZENKO, W., DUGGAN, M. E., LASWELL, W. L., VASSALLO, L. M., SHAFER, J. A., ANDERSON, P. S., FRIEDMAN, P. A., HARTMAN, G. D. AND GOULD, R. J.: Non-peptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J. Pharmacol. Exp. Ther. 272: 20-32, 1995.
24. MÜLLER, T. H., SCHURER, H., WALDMANN, L., BAUER, E., HIMMELSBACH, F. AND BINDER, K.: Oral activity of BIBU 104, a prodrug of the non-peptide fibrinogen receptor antagonist BIBU 52, in mice and monkeys. Thromb. Haemostas. 69: 975, 1993.
25. MÜLLER, T. H., WEISENBERGER, H., BRIKL, R., KIRCHNER, M., NARJES, H., HIMMELSBACH, F., GUTH, B. AND KRAUSE, J.: Pharmacodynamics and kinetics of BIBU 52, a platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug BIBU 104 in man. Thromb. Haemost. 73: 1445, 1995.
26. NICHOLSON, N. S., PANZER-KNODLE, S. G., SALYERS, A. K., TAITE, B. B., SZALONY, J. A., HAAS, N. F., KING, L. W., ZABLOCKI, J. A., KELLER, B. T., BROSCHAT, K., ENGLEMAN, V. W., HERIN, M., JACQMIN, P. AND FEIGEN, L. P.: SC-54684A: An orally active inhibitor of platelet aggregation. Circulation 91:403-410, 1995.
27. OHMAN, E. M., KLEIMAN, N. S., TALLEY, J. D., GACIOCH, G., NAVETTA, F. I., CARNEY, R. J., WORLEY, S., ANDERSON, H. V., COHEN, M., KEREIAKES, D., JOSEPH, D., SIGMON, K. N. AND TOPOL, E. J.: Simultaneous platelet glycoprotein IIb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction. Circulation 90: I-564, 1994.
28. OJIMA, I., CHAKRAVARTY, S. AND DONG, Q.: Antithrombotic agents: From RGD to peptide mimetics. Bioorgan. Med. Chem. 3: 337-360, 1995.
29. PEERLINCK, K., DE LEPELEIRE, I., GOLDBERG, M., FARRELL, D., BARRETT, J., HAND, E., PANEBIANCO, D., DECKMYN, H., VERMYLEN, J. AND ARNOUT, J.: MK-383 (L-700,462), a selective nonpeptide platelet GPIIb/IIIa antagonist, is active in man. Circulation 88: 1512-1517, 1993.
30. PRUEKSARITANONT, T., GORHAM, L. M., NAUE, J. A., HAMILL, T. G., ASKEW, B. C. AND VYAS, K. P.: Disposition of L-738,167, a potent and long acting fibrinogen receptor antagonist, in dogs: Dose-dependent pharmacokinetics. Drug Metab. Dispos. 25: 355-361, 1997.
31. RAMJIT, D. R., LINCH, J. J., SITKO, G. R., MELLOTT, M. J., HOLAHAN, M. A., STABILITO, I. I., STRANIERI, M. T., ZHANG, G., LYNCH, R. J., MANNO, P. D., CHANG, C. T.-C., NUTT, R. F., BRADY, S. F., VEBER, D. F., ANDERSON, P. S., SHEBUSKI, R. J., FRIEDMAN, P. A. AND GOULD, R. J.: Antithrombotic effects of MK-0852, a novel platelet fibrinogen receptor antagonist, in canine models of thrombosis. J. Pharmacol. Exp. Ther. 266: 1501-1511, 1993.
32. RODGERS, R. P. C. AND LEVIN, J.: A critical reappraisal of the bleeding time. Semin. Thromb. Hemost. 16: 1-20, 1990.
33. SCHULMAN, S. P., GOLDSCHMIDT-CLERMONT, P. J., NAVETTA, F. I., CHANDRA, N. C., GUERCI, A. D., CALIFF, R. M., FERGUSON, J. J., WILLERSON, J. T., WOLFE, C. L., BAHR, R., YAKUBOV, S. J., NYGAARD, T. W., MASON, S. J., BRASHEARS, L., CHARO, I., DUMEE, C., KITT, M. M. AND GERTSENBLITH, G.: Integrelin in unstable angina: A double-blind randomized trial. Circulation 88: I-608, 1993.
34. SIMOONS, M. L., JAN DE BOER, M., VAN DEN BRAND, M. J. B. M., VAN MILTENBURG, A. J. M., HOORNTJE, J. C. A., HEYNDRICKX, G. R., VAN DER WIEKEN, L. R., DE BONO, D., RUTSCH, W., SCHAIBLE, T. F., WEISMAN, H. F., KLOOTWIJK, P., NIJSSEN, K. M., STIBBE, J., DE FEYTER, P. J. AND EUROPEAN COOPERATIVE STUDY GROUP Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 89: 596-603, 1994.
35. SIMPFENDORFER, C., KOTTKE-MARCHANT, K. AND TOPOL, E. J.: First experience with chronic platelet GPIIb/IIIa receptor blockade: A pilot study of xemlofiban an orally active antagonist in unstable angina patients eligible for PTCA. J. Am. Coll. Cardiol. 27: 242A, 1996.
36. STEINER, B., JONES, C. R., VAN HEININGEN, P. N. M., JONKMAN, J. H. G., CARROLL, R. C. AND KOUNS, W. C.: TRAP-induced ex vivo platelet aggregation might be a useful method to predict antithrombotic efficacy. Blood 82: 284a, 1993.
37. STEINER, B., ALIG, L., BLACKBURN, B., BUNTING, S., HÜRZELER, M., SCHMITT, M., WEISS, S. AND WELLER, T.: A new class of orally active GPIIb/IIIa antagonists. Blood 86: 91a, 1995.
38. SZALONY, J. A., HAAS, N. F., SALYERS, A. K., TAITE, B. B., NICHOLSON, N. S., MEHROTRA, D. V. AND FEIGEN, L. P.: Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 91: 411-416, 1995.
39. TCHENG, J. E., HARRINGTON, R. A., KOTTKE-MARCHANT, K., KLEIMAN, N. S., ELLIS, S. G., KEREIAKES, D. J., MICK, M. J., NAVETTA, F. I., SMITH, J. E., WORLEY, S. J., MILLER, J. A., JOSEPH, D. M., SIGMON, K. N., KITT, M. M., DUMEE, C. P., CALIFF, R. M. AND TOPOL, E. J.: Multicenter randomized double-blind placebo controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation 91: 2151-2157, 1995.
40. THÉROUX, P., WHITE, H., DAVID, D., VAN DE WERF, F., NIENABER, C. A., CHARBONNIER, B., ERHARDT, L., GILL, J., HILLIS, W. S., JENNINGS, G., TAN, L-B., DESCHENES, N., FITZPATRICK, V. AND SAX, F. L.: A heparin-controlled study of MK-383 in unstable angina. Circulation 90: I-231, 1994.
41. THÉROUX, P., KOUZ, S., ROY, L., KNUDTSON, M. L., DIODATI, J. G., MARQUIS, J-F., NASMITH, J., FUNG, A. Y., BOUDREALT, J-R., DELAGE, F., DUPUIS, R., KELLS, C., BOKSLAG, M., STEINER, B. AND RAPOLD, H. J.: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian lamifiban study. Circulation 94: 899-905, 1996.
42. TOPOL, E. J.: Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am. Heart J. 130: 666-672, 1995.
43. TOPOL, E. J., CALIFF, R. M., WEISMAN, H. F., ELLIS, S. G., TCHENG, J. E., WORLEY, S., IVANHOE, R., GEORGE, B. S., FINTEL, D., WESTON, M., SIGMON, K., ANDERSON, K. M., LEE, K. L., WILLERSON, J. T. AND EPIC INVESTIGATORS: Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis. Results at six months. Lancet 343: 881-886, 1994.
44. WELLER, T., ALIG, L., BERESINI, M., BLACKBURN, B., BUNTING, S., HADVÁRY, P., HÜRZELER MÜLLER, M., KNOPP, D., LEVET-TRAFIT, B., LIPARI, M. T., MODI, N. B., MÜLLER, M., REFINO, C. J., SCHMITT, M., SCHÜNHOLZER, P., WEISS, S. AND STEINER, B.: Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J. Med. Chem. 39: 3139-3147, 1996.